NEW YORK, Nov 16 (Reuters) - Bayer AG (BAYG.DE: Quote, Profile, Research) questioned on Thursday the findings of researchers who said a clinical trial had uncovered evidence of increased risk of heart problems linked to the popular analgesic naproxen, the active ingredient in Bayer’s painkiller Aleve.
